Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo

Inclusion criteria

• Male or female subjects aged between 18 and 70 years
• Positive clinical findings of athlete's foot, limited to interdigital spaces, with a total athlete's foot severity score (AFSS) of at least 5 and not exceeding 10 points for the signs and symptoms of athlete's foot, and no sign or symptom scoring 'severe'

Exclusion criteria

• Clinical history suggestive of intolerance or allergies to one of the products or the ingredients of the products
• Plantar tinea pedis ("Mocassin-type")
• Onychomycosis of any toe
• Previous treatment with a systemic antifungal within 6 months prior to screening
• Previous treatment of feet with a topical antifungal within 4 weeks prior to screening
• Previous treatment with a topical antifungal applied to other areas of the body than feet within 2 weeks prior to screening
• Previous treatment of any topical medication applied to the feet within 2 weeks prior to screening